

# Giuseppe Gargiulo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9286137/giuseppe-gargiulo-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110  
papers

3,059  
citations

29  
h-index

52  
g-index

126  
ext. papers

4,000  
ext. citations

5.8  
avg, IF

5.15  
L-index

#	Paper	IF	Citations
110	The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> , 15, 229-230	5	
109	Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial.. <i>Cardiovascular Drugs and Therapy</i> , <b>2022</b> , 1	3.9	1
108	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial.. <i>Journal of the American Heart Association</i> , <b>2022</b> , e024291	6	0
107	Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. <i>Global &amp; Regional Health Technology Assessment</i> , <b>2022</b> , 9, 17-26	0.2	
106	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. <i>EuroIntervention</i> , <b>2021</b> ,	3.1	5
105	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , <b>2021</b> , 17, e898-e909	3.1	11
104	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, e29-e30 <sup>6.4</sup>		
103	Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial". <i>Circulation</i> , <b>2021</b> , 143, e797-e798	16.7	
102	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021965	6	9
101	Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2021</b> , 47, 950-961	5.3	4
100	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: a Multicenter Randomized Open-label Trial in Patients with ST-elevation Myocardial Infarction Referred for Primary Percutaneous Intervention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1116-1126	3.3	5
99	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , <b>2021</b> , 42, 1025-1038	9.5	23
98	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, f50-f60	6.4	14
97	Consolidating the value of the standardised ARC-HBR definition. <i>EuroIntervention</i> , <b>2021</b> , 16, 1126-1128	3.1	4
96	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 375-388	15.1	19
95	Cardiovascular mortality and morbidity in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest: a systematic review and meta-analysis. <i>EuroIntervention</i> , <b>2021</b> , 16, e1245-e1253	3.1	1
94	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2021</b> ,	4.3	0

93	Antithrombotic treatment strategies after PCI - AuthorsTreply. <i>Lancet, The</i> , <b>2020</b> , 395, 867-868	40	
92	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2020</b> , 73, 893-901	0.7	4
91	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. <i>Circulation</i> , <b>2020</b> , 142, 441-454	16.7	40
90	Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. <i>European Heart Journal</i> , <b>2020</b> , 41, 1701-1702	9.5	3
89	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. <i>EuroIntervention</i> , <b>2020</b> , 16, 371-379	3.1	61
88	Complete Revascularization in Acute and Chronic Coronary Syndrome. <i>Cardiology Clinics</i> , <b>2020</b> , 38, 491-505	5	2
87	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 3743-3749	9.5	45
86	Lugar de acceso y tipo de anticoagulante en pacientes con síndrome coronario agudo en clase Killip avanzada o con parada cardíaca extrahospitalaria. <i>Revista Espanola De Cardiologia</i> , <b>2020</b> , 73, 893-901	1.5	2
85	Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 660-666	1.9	3
84	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , <b>2019</b> , 57, 44-54	1.4	6
83	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1335-1343	40	297
82	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 810-822	6.9	9
81	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 758-774	15.1	11
80	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal</i> , <b>2019</b> , 40, 3757-3767	9.5	125
79	Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 2116-2118	5	3
78	Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. <i>EuroIntervention</i> , <b>2019</b> , 15, e269-e278	3.1	2
77	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. <i>International Journal of Cardiology</i> , <b>2019</b> , 277, 60-65	3.2	1
76	Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. <i>International Journal of Cardiology</i> , <b>2018</b> , 260, 42-46	3.2	5

75	Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 6-11	3	9
74	Regulates Vascular Function and Endothelial Cells Behavior. <i>Hypertension</i> , <b>2018</b> , 71, 507-517	8.5	21
73	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 36-50	5	30
72	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1231-1242	15.1	27
71	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , <b>2018</b> , 392, 940-949	40	356
70	Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , <b>2017</b> , 19, 2	4.2	4
69	Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 90, E73-E84	2.7	14
68	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 606	8	1
67	Response by Valgimigli and Gargiulo to Letter Regarding Article, "A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?". <i>Circulation</i> , <b>2017</b> , 135, e1037-e1038	16.7	
66	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	37
65	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2592-2592	15.1	95
64	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 17-25	8	30
63	Deciding on the Duration of Dual Antiplatelet Therapy-When the Choice Between 2 Evils Is Still Evil. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 488-489	16.2	3
62	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 2025-2030	3	12
61	Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. <i>European Heart Journal</i> , <b>2017</b> , 38, 2948-2956	9.5	240
60	Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 7	8.7	4
59	Meta-Analysis of Effect of Body Mass Index on Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 308-316	3	28
58	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. <i>EuroIntervention</i> , <b>2017</b> , 13, 78-86	3.1	15

57	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives. <i>EuroIntervention</i> , <b>2017</b> , 13, 717-733 <sup>3.1</sup>		24
56	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 795-803	16.2	48
55	Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1780-9	5	18
54	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 2280-2288	5	17
53	Renal dysfunction and transcatheter aortic valve implantation outcomes. <i>Expert Review of Cardiovascular Therapy</i> , <b>2016</b> , 14, 1315-1323	2.5	10
52	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. <i>BMJ, The</i> , <b>2016</b> , 355, i5483	5.9	34
51	Risk prediction of contrast-induced nephropathy by ACEF score in patients undergoing coronary catheterization. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17, 524-9	1.9	13
50	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 475-86	4.3	12
49	Developing drugs for use before, during and soon after percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 803-18	4	9
48	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. <i>American Heart Journal</i> , <b>2016</b> , 174, 95-102	4.9	37
47	Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture. <i>JACC: Cardiovascular Imaging</i> , <b>2016</b> , 9, 210-1	8.4	4
46	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. <i>EuroIntervention</i> , <b>2016</b> , 12, e152-9	3.1	6
45	A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , <b>2016</b> , 12, e1047-e1056 <sup>3.1</sup>		53
44	Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17, 843-9	1.9	7
43	Parenteral Antiplatelet Agents in PCI <b>2016</b> , 415-420		
42	A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?. <i>Circulation</i> , <b>2016</b> , 134, 1881-1906	16.7	53
41	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2016</b> , 165, 334-44	8	84
40	Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?: Insights From Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 976-7	5	

39	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 253-62	4.3	43
38	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. <i>International Journal of Cardiology</i> , <b>2016</b> , 203, 264-6	3.2	18
37	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1888-1896	3	28
36	Bivalirudina frente a heparina no fraccionada en síndromes coronarios agudos: ¿hay un vencedor?. <i>Revista Espanola De Cardiologia</i> , <b>2016</b> , 69, 721-724	1.5	
35	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 695-6	3.2	2
34	Five-year outcomes of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with left main coronary artery disease: An updated meta-analysis of randomized trials and adjusted observational studies. <i>International Journal of Cardiology</i> , <b>2015</b> , 195, 79-81	3.2	19
33	Cyphering the mechanism of late failure of bioresorbable vascular scaffolds in percutaneous coronary intervention of the left main coronary artery. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, e95-e97	5.7	1
32	Early discharge after transfemoral transcatheter aortic valve implantation. <i>Heart</i> , <b>2015</b> , 101, 1485-90	5.1	66
31	One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1205.e5-6	3.8	
30	Prevalence and characteristics of true and apparent treatment resistant hypertension in the Campania Salute Network. <i>International Journal of Cardiology</i> , <b>2015</b> , 184, 417-419	3.2	6
29	New-onset coronary aneurism and late-acquired incomplete scaffold apposition after full polymer jacket of a chronic total occlusion with bioresorbable scaffolds. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, e41-e43	5	7
28	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , <b>2015</b> , 189, 77-8	3.2	3
27	Embolic protection devices during carotid artery stenting: Is there a difference between proximal occlusion and distal filter?. <i>International Journal of Cardiology</i> , <b>2015</b> , 187, 592-3	3.2	3
26	Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality?. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1639-1640	15.1	24
25	Dermcidin: a skeletal muscle myokine modulating cardiomyocyte survival and infarct size after coronary artery ligation. <i>Cardiovascular Research</i> , <b>2015</b> , 107, 431-41	9.9	22
24	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. <i>BMJ, The</i> , <b>2015</b> , 351, h5392	5.9	77
23	Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 85, 1150-61	2.7	27
22	Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes. <i>Frontiers in Cardiovascular Medicine</i> , <b>2015</b> , 2, 13	5.4	5

21	New cerebral lesions at magnetic resonance imaging after carotid artery stenting versus endarterectomy: an updated meta-analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129209	3.7	20
20	Radial versus femoral access for cardiac catheterisation - AuthorsTrepley. <i>Lancet, The</i> , <b>2015</b> , 386, 2394	4.0	6
19	Moderate and severe preoperative chronic kidney disease worsen clinical outcomes after transcatheter aortic valve implantation: meta-analysis of 4992 patients. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8, e002220	6	49
18	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients. <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 86, 518-27	2.7	61
17	Time for science to catch up with clinical practice?. <i>Journal of Thoracic Disease</i> , <b>2015</b> , 7, E603-6	2.6	2
16	Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. <i>EuroIntervention</i> , <b>2015</b> , 11, 690-7	3.1	37
15	Antithrombotic therapy in TAVI patients: changing concepts. <i>EuroIntervention</i> , <b>2015</b> , 11 Suppl W, W92-5	3.1	21
14	Cerebral embolic lesions detected with diffusion-weighted magnetic resonance imaging following carotid artery stenting: a meta-analysis of 8 studies comparing filter cerebral protection and proximal balloon occlusion. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 1177-83	5	63
13	Increased mortality after transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis and low ejection fraction: a meta-analysis of 6898 patients. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 32-9	3.2	39
12	Meta-analysis of mortality outcomes and mitral regurgitation evolution in 4,839 patients having transcatheter aortic valve implantation for severe aortic stenosis. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 875-82	3	45
11	Cardiac side effects of chemotherapy: state of art and strategies for a correct management. <i>Current Vascular Pharmacology</i> , <b>2014</b> , 12, 106-16	3.3	19
10	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. <i>Expert Review of Cardiovascular Therapy</i> , <b>2014</b> , 12, 1185-203	2.5	19
9	Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2566-71	3.2	24
8	Genetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000086	6	40
7	Unexpected preserved brain perfusion imaging despite severe and diffuse atherosclerosis of supra-aortic trunks. <i>Cardiovascular Journal of Africa</i> , <b>2013</b> , 24, e12-4	0.7	4
6	Use of statins in lower extremity artery disease: a review. <i>BMC Surgery</i> , <b>2012</b> , 12 Suppl 1, S15	2.3	13
5	Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication. <i>BMC Surgery</i> , <b>2012</b> , 12 Suppl 1, S19	2.3	10
4	Balancing hemorrhagic and thrombotic complications in a patient with a very late paclitaxel-eluting stent thrombosis: a clinical case report. <i>Journal of Cardiovascular Medicine</i> , <b>2011</b> , 12, 366-9	1.9	3

3	EGFR trans-activation by urotensin II receptor is mediated by E3 ubiquitin ligase recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. <i>Basic Research in Cardiology</i> , <b>2011</b> , 106, 577-89	11.8	50
2	Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2011</b> , 300, H1983-9	5.2	21
1	Induction of mitogen-activated protein kinases is proportional to the amount of pressure overload. <i>Hypertension</i> , <b>2010</b> , 55, 137-43	8.5	21